Wine, beer, or spirits: what a 340,000-person study reveals about alcohol and health

Alcohol's effect on health has occupied researchers for decades, and a new study offers a significant contribution to that debate by tracking more than 340,000 adults for over a decade. Researchers carefully recorded participants' beverage preferences and consumption levels, then linked that data to mortality outcomes.
The study's clearest finding was that heavy drinking raised mortality risk regardless of which beverage people preferred. Participants who consumed alcohol heavily faced significantly higher death risk than lighter drinkers, no matter whether they favored wine, beer, or spirits.
At low to moderate consumption levels, though, the picture grew more complicated. Researchers found that beer, spirits, and cider drinkers were linked to higher mortality risk, while wine drinkers showed lower risk by comparison.
The most striking finding was that moderate wine drinkers had a 21% lower risk of cardiovascular death compared with people who rarely or never drank. That gap prompted researchers to ask why beverage choice might matter so much.
Experts caution that the difference may not stem directly from alcohol itself, but from lifestyle differences among people who prefer different beverages. Wine drinkers, studies have repeatedly shown, tend to eat more balanced diets, smoke less, and have higher socioeconomic status on average.
Wine also contains polyphenols, including resveratrol, which is especially concentrated in red wine and has historically been linked to cardiovascular protection. But scientists note the compound's direct effect appears small, and lifestyle factors are likely far more decisive.
The study's authors warn against interpreting the findings as evidence that light drinking is healthy. Health authorities maintain that alcohol raises cancer risk at every level of consumption and that no safe threshold has been established.
The research also raises a meaningful question for public health policy: should guidance be beverage-specific, or should it continue to focus on overall alcohol consumption? Experts broadly agree the current evidence still supports focusing on total intake rather than beverage type.
Because the study is observational, it cannot establish causation — only an association. The researchers say further studies are needed to confirm the findings and clarify the mechanisms behind them.
In the end, the safest advice on alcohol remains unchanged: moderation, and reducing consumption where possible. The claim that wine is inherently "safer" than other beverages remains a finding that warrants cautious interpretation.
Read next

What are the signs of compulsive porn use, and what does recovery look like?
After a former Team GB Olympian spoke publicly about overcoming compulsive porn use, experts explain the warning signs to watch for and the treatment paths available. Specialists say the behavior is a frequently overlooked form of behavioral addiction.

Millions in England face longer mental health care waits as providers plan cuts
A survey of NHS mental health providers in England found seven in ten expect to reduce or close services, while more than half anticipate job losses. Experts warn the cuts could delay care for millions of adults and children already facing surging demand.

Maternity unit suspension in rural Devon leaves expectant mothers facing stark choices
The suspension of birthing services at one of England's most remote hospitals is forcing expectant mothers in North Devon to choose between traveling two hours to the nearest maternity unit or paying for a hotel near the hospital before labor begins.

Is the biotech capital of the world shifting from Boston to San Francisco?
For decades, Boston's Kendall Square has been considered the world's biotech capital. Now the San Francisco Bay Area's AI-driven drug discovery boom is drawing talent and capital west, raising questions about whether the center of gravity is shifting.

Sanofi drug shortage leaves Pompe disease patients scrambling for treatment
Sanofi is facing shortages of two enzyme-replacement medicines used to treat Pompe disease, a rare and progressive muscle-wasting disorder. Patient advocacy groups say interrupted treatment can cause irreversible harm.